CIA
FLNA

Capital Impact Advisors’s Filana Therapeutics FLNA Stock Holding History

Capital Impact Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,458
Closed -$122 – 220
2014
Q3 		$122 Hold
4,458
– – ﹤0.01% 197
2014
Q2 		$179K Buy
+4,458
New +$165K 0.13% 110

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Impact Advisors's FLNA Position: Q4 2014 in Review

Capital Impact Advisors sold out of Filana Therapeutics (FLNA) in Q4 2014, closing a stake of 4,458 shares — an estimated $122 sold.

Capital Impact Advisors first reported a position in FLNA in Q2 2014 and held it in 2 quarters. The position peaked at $179K in Q2 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q4 2014.

  • Capital Impact Advisors reported no remaining Filana Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Capital Impact Advisors sold 4,458 Filana Therapeutics shares in Q4 2014, an estimated $122.
  • Capital Impact Advisors first reported a position in Filana Therapeutics in Q2 2014 and held it in 2 quarters.
  • Capital Impact Advisors's Filana Therapeutics position peaked at $179K in Q2 2014.
  • 66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2014.

Based on Capital Impact Advisors's 13F filing for Q4 2014, filed 25 Feb 2015.